课题基金 / 基金详情

Buccal Nanocytological Risk Stratification to Personalize Lung Cancer Screening

Buccal Nanocytological Risk Stratification to Personalize Lung Cancer Screening
口腔纳米细胞学风险分层可实现个体化肺癌筛查
批准号:
9201982
负责人:
HARIHARAN SUBRAMANIAN
金额:
$77.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2018-08-31

项目摘要

项目成果

HARIHARAN SUBRAMANIAN的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 该SBIR项目的目标是开发用于FDA临床试验的商业级纳米细胞学系统, 肺癌风险分层测试的后续商业化,以个性化肺癌筛查。 肺癌是美国癌症死亡的主要原因。 与其倾向于在晚期被诊断有关,因为疾病的潜在可治愈阶段是 临床上通常是沉默的。现有的筛查肺癌的方法无论从灵敏度还是 或功效/成本效益的观点。虽然低剂量CT(LDCT)已显示出其出色的前景, LDCT的敏感性和特异性,其局限性是其不可接受的高假阳性率, 测试结果实际上是假阳性(由于患病率低),导致过度诊断。因此 两步法,其中第一项测试(风险分层)将能够识别高风险患者 其次是更具侵入性/昂贵的测试,如LDCT(类似于巴氏涂片阴道镜检查范例, 宫颈癌)将是肺癌筛查的理想解决方案。NanoCytomics正在开发一种风险 肺癌的分层测试,这将是低成本,高灵敏度,微创, 简单到可以在初级保健办公室通过简单的颊拭子进行 上皮在这个直接进入第二阶段的项目中,NanoCytomics将开发一个独立的高通量 分波光谱(HT-PWS)显微镜,符合所有美国和国际标准, 将开发制造以及符合法规的产品。PWS显微镜(或简称, 纳米细胞学)在西北大学开发的已被广泛证明量化的统计 细胞纳米级组织的性质并识别颊上皮细胞中的早期癌性变化, 与肺癌有关的蛋白质在之前的I期研究中,NanoCytomics开发了一种 基于面包板的高通量系统原型,比第一个快两个数量级 第二代PWS显微镜,并为颊PWS开发了一个强大的标准操作程序, 样品的合格率提高到~100%。作为下一步,NanoCytomics努力开发一种 带嵌入式PC模块的独立商业级HT-PWS系统,用于多中心FDA试验 以及随后的商业化。二期项目还将侧重于临床预测规则开发 和盲法验证研究。我们的设想是,PWS分析从颊粘膜刷取的细胞, 成为一种风险分层工具,可由初级保健医生作为年度检查的一部分进行 以确定可能从进一步筛查中获益的患者子集。如果口腔PWS试验呈阳性, 将向患者提供更昂贵/侵入性的测试,例如低剂量CT。
英文摘要
Project Summary/Abstract This goal of this SBIR project is to develop a commercial grade Nanocytology system for FDA clinical trials and subsequent commercialization of a lung cancer risk stratification test to personalize lung cancer screening. Lung cancer is the leading cause of cancer deaths in the U.S. The reason for the lethality of lung cancer relates to its tendency to be diagnosed at a late stage, given that potentially curable stages of disease are often clinically silent. Existing approaches to screen lung cancer have been inadequate from either sensitivity or an efficacy/cost-effectiveness perspective. While low-dose CT (LDCT) has shown promise with its excellent sensitivity and specificity, limitation of LDCT is its unacceptably high false positive rate with most of the positive test results actually being false positives (due to the low prevalence rate) leading to overdiagnosis. Hence the two step approach wherein the first test (risk stratification) will be able to identify the patients with high risk followed by a more intrusive/expensive test such as LDCT (similar to Pap smear à colposcopy paradigm for cervical cancer) would be an ideal solution for lung cancer screening. NanoCytomics is developing a risk stratification test for lung cancer which would be low cost, highly sensitive, and minimally invasive and will be simple enough to be performed in a primary care office by means of a simple buccal swab of the cheek epithelium. In this direct to Phase II project, NanoCytomics will develop a self-contained high-throughput partial wave spectroscopic (HT-PWS) microscope that is compliant with all US and International standards of manufacturing as well as that is regulatory compliant will be developed. PWS microscopy (or simply, Nanocytology) developed at Northwestern University has extensively been shown to quantify the statistical properties of cellular nanoscale organization and identify early cancerous changes in buccal epithelial cells, which are associated with lung cancer. In the previous Phase I-type research, NanoCytomics had developed a bread board based high-throughput system prototype that is two orders of magnitude faster than the first generation PWS microscope as well as developed a robust standard operating procedure for buccal PWS that improved the acceptance rate of samples to ~ 100%. As a next step, NanoCytomics endeavors to develop a self-contained commercial grade HT-PWS system with an embedded PC module for multi-center FDA trials and subsequent commercialization. The Phase II project will also focus on clinical prediction rule development and a blinded validation study. Our vision is that PWS analysis of cells brushed from the buccal mucosa may become a risk stratification tool that can be performed by a primary care physician as part of an annual exam to identify the subset of patients who may benefit from further screening. If the buccal PWS test is positive, the patients will be offered more expensive/invasive tests such as Low dose CT.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
NanoCytology to mitigate overdiagnosis of prostate cancer
  • 批准号:
    9177786
  • 项目类别:
  • 资助金额:
    $71.34万
  • 财政年份:
    2015
  • 负责人:
    HARIHARAN SUBRAMANIAN
  • 依托单位:
COLORECTAL CANCER (CRC) SCREENING VIA RECTAL NANOCYTOLOGY
  • 批准号:
    8395166
  • 项目类别:
  • 资助金额:
    $15.32万
  • 财政年份:
    2012
  • 负责人:
    HARIHARAN SUBRAMANIAN
  • 依托单位:
COLORECTAL CANCER (CRC) SCREENING VIA RECTAL NANOCYTOLOGY
  • 批准号:
    8725273
  • 项目类别:
  • 资助金额:
    $74.03万
  • 财政年份:
    2012
  • 负责人:
    HARIHARAN SUBRAMANIAN
  • 依托单位:
海外基金